An Update of Ischemic Hepatitis: A Review
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Published
Jul 22, 2024
Abstract
Ischemic hepatitis, also referred to as shock liver, is a condition that is marked by liver damage that is the consequence of an insufficient blood supply to the liver. This article offers a thorough examination of ischemic hepatitis, encompassing its pathophysiology, clinical presentation, diagnosis, treatment, and prognosis. Understanding the causes, risk factors, and management strategies of ischemic hepatitis is crucial for improving the outcomes of affected individuals. Our objective is to illuminate this condition and improve the understanding of healthcare professionals and patients by investigating the most recent research and future developments in this field.
##plugins.themes.bootstrap3.article.details##
Keywords
Ischemic Hepatitis, Diagnosis, Prognosis, Therapeutics, Outcomes
References
1. Waseem N, Chen PH. Hypoxic hepatitis: A review and clinical update. J Clin Transl Hepatol 2016; 4(3):263-268. DOI: https://doi.org/10.14218/JCTH.2016.00022
2. Ciobanu AO, Gherasim L. Ischemic hepatitis - Intercorrelated pathology. Maedica (Bucur) 2018; 13(1):5-11.
3. Soleimanpour H, Safari S, Rahmani F, Nejabatian A, Alavian SM. Hepatic shock differential diagnosis and risk factors: A review article. Hepat Mon 2015; 15(10):e27063. DOI: https://doi.org/10.5812/hepatmon.27063
4. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: Clinical presentation and pathogenesis. Am J Med 2000; 109(2):109-113. DOI: https://doi.org/10.1016/s0002-9343(00)00461-7
5. Damasceno TA, Scorzoni A Filho, Chahud F, Rodrigues AJ, Vicente WV, Evora PR. Cardiopulmonary bypass ischemic hepatitis reported in five patients. Braz J Cardiovasc Surg 2016; 31(4):330-333. DOI: https://doi.org/10.5935/1678-9741.20160059
6. Wang D, Yin Y, Yao Y. Advances in sepsis-associated liver dysfunction. Burns Trauma 2014; 2(3):97-105. DOI: https://doi.org/10.4103/2321-3868.132689
7. Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic kidney disease, cardiovascular disease and non-alcoholic fatty liver disease: A new triumvirate? J Clin Med 2021; 10(9):2040. DOI: https://doi.org/10.3390/jcm10092040
8. Schiffrin EL. Circulatory therapeutics: Use of antihypertensive agents and their effects on the vasculature. J Cell Mol Med 2010; 14(5):1018-1029. DOI: https://doi.org/10.1111/j.1582-4934.2010.01056.x
9. Fargo MV, Grogan SP, Saguil A. Evaluation of jaundice in adults. Am Fam Physician 2017; 95(3):164-168.
10. Ciobanu AO, Gherasim L. Ischemic hepatitis - intercorrelated pathology. Maedica (Bucur) 2018; 13(1):5-11.
11. Taylor RM, Tujios S, Jinjuvadia K, Davern T, Shaikh OS, Han S, Chung RT, Lee WM, Fontana RJ. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. Dig Dis Sci 2012; 57(3):777-785. DOI: https://doi.org/10.1007/s10620-011-1918-1
12. Toma D, Lazar O, Bontas E. Acute liver failure. Liver Diseases 2019; 2019:369-380. DOI: https://doi.org/10.1007/978-3-030-24432-3_32
13. Tyagi A, Pruthi HS. Ischemic hepatitis. Med J Armed Forces India 1999; 55(4):359-360. DOI: https://doi.org/10.1016/S0377-1237(17)30375-1
14. Mohamed DI, Ezzat SF, Elayat WM, El-Kharashi OA, El-Kareem HFA, Nahas HHA, Abdel-Wahab BA, Alshawwa SZ, Saleh A, Helmy YA, Khairy E, Saied EM. Hepatoprotective role of carvedilol against ischemic hepatitis associated with acute heart failure via targeting miRNA-17 and mitochondrial dynamics-related proteins: An in vivo and in silico study. Pharmaceuticals (Basel) 2022; 15(7):832. DOI: https://doi.org/10.3390/ph15070832
15. Obed A, Alsakarneh S, Abuassi M, Bashir A, Ahmad BA, Jarrad A, Lorf T, Almeqdadi M. Ischemic reperfusion injury after liver transplantation: Is there a place for conservative management? Gastroenterology Res 2023; 16(1):50-55. DOI: https://doi.org/10.14740/gr1584
16. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012; 2012(5):CD008344. DOI: https://doi.org/10.1002/14651858.CD008344.pub2
17. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012; 298:229-317. DOI: https://doi.org/10.1016/B978-0-12-394309-5.00006-7
18. Hefler J, Marfil-Garza BA, Pawlick RL, Freed DH, Karvellas CJ, Bigam DL, Shapiro AMJ. Preclinical models of acute liver failure: A comprehensive review. PeerJ 2021; 9:e12579. DOI: https://doi.org/10.7717/peerj.12579
19. Rahman TM, Hodgson HJ. Animal models of acute hepatic failure. Int J Exp Pathol 2000; 81(2):145-157. DOI: https://doi.org/10.1046/j.1365-2613.2000.00144.x
20. Humphries C, Dear JW. Novel biomarkers for drug-induced liver injury. Clin Toxicol (Phila) 2023; 61(8):567-572. DOI: https://doi.org/10.1080/15563650.2023.2259089
21. Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022; 7(1):287. DOI: https://doi.org/10.1038/s41392-022-01119-3
2. Ciobanu AO, Gherasim L. Ischemic hepatitis - Intercorrelated pathology. Maedica (Bucur) 2018; 13(1):5-11.
3. Soleimanpour H, Safari S, Rahmani F, Nejabatian A, Alavian SM. Hepatic shock differential diagnosis and risk factors: A review article. Hepat Mon 2015; 15(10):e27063. DOI: https://doi.org/10.5812/hepatmon.27063
4. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: Clinical presentation and pathogenesis. Am J Med 2000; 109(2):109-113. DOI: https://doi.org/10.1016/s0002-9343(00)00461-7
5. Damasceno TA, Scorzoni A Filho, Chahud F, Rodrigues AJ, Vicente WV, Evora PR. Cardiopulmonary bypass ischemic hepatitis reported in five patients. Braz J Cardiovasc Surg 2016; 31(4):330-333. DOI: https://doi.org/10.5935/1678-9741.20160059
6. Wang D, Yin Y, Yao Y. Advances in sepsis-associated liver dysfunction. Burns Trauma 2014; 2(3):97-105. DOI: https://doi.org/10.4103/2321-3868.132689
7. Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic kidney disease, cardiovascular disease and non-alcoholic fatty liver disease: A new triumvirate? J Clin Med 2021; 10(9):2040. DOI: https://doi.org/10.3390/jcm10092040
8. Schiffrin EL. Circulatory therapeutics: Use of antihypertensive agents and their effects on the vasculature. J Cell Mol Med 2010; 14(5):1018-1029. DOI: https://doi.org/10.1111/j.1582-4934.2010.01056.x
9. Fargo MV, Grogan SP, Saguil A. Evaluation of jaundice in adults. Am Fam Physician 2017; 95(3):164-168.
10. Ciobanu AO, Gherasim L. Ischemic hepatitis - intercorrelated pathology. Maedica (Bucur) 2018; 13(1):5-11.
11. Taylor RM, Tujios S, Jinjuvadia K, Davern T, Shaikh OS, Han S, Chung RT, Lee WM, Fontana RJ. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis. Dig Dis Sci 2012; 57(3):777-785. DOI: https://doi.org/10.1007/s10620-011-1918-1
12. Toma D, Lazar O, Bontas E. Acute liver failure. Liver Diseases 2019; 2019:369-380. DOI: https://doi.org/10.1007/978-3-030-24432-3_32
13. Tyagi A, Pruthi HS. Ischemic hepatitis. Med J Armed Forces India 1999; 55(4):359-360. DOI: https://doi.org/10.1016/S0377-1237(17)30375-1
14. Mohamed DI, Ezzat SF, Elayat WM, El-Kharashi OA, El-Kareem HFA, Nahas HHA, Abdel-Wahab BA, Alshawwa SZ, Saleh A, Helmy YA, Khairy E, Saied EM. Hepatoprotective role of carvedilol against ischemic hepatitis associated with acute heart failure via targeting miRNA-17 and mitochondrial dynamics-related proteins: An in vivo and in silico study. Pharmaceuticals (Basel) 2022; 15(7):832. DOI: https://doi.org/10.3390/ph15070832
15. Obed A, Alsakarneh S, Abuassi M, Bashir A, Ahmad BA, Jarrad A, Lorf T, Almeqdadi M. Ischemic reperfusion injury after liver transplantation: Is there a place for conservative management? Gastroenterology Res 2023; 16(1):50-55. DOI: https://doi.org/10.14740/gr1584
16. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012; 2012(5):CD008344. DOI: https://doi.org/10.1002/14651858.CD008344.pub2
17. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012; 298:229-317. DOI: https://doi.org/10.1016/B978-0-12-394309-5.00006-7
18. Hefler J, Marfil-Garza BA, Pawlick RL, Freed DH, Karvellas CJ, Bigam DL, Shapiro AMJ. Preclinical models of acute liver failure: A comprehensive review. PeerJ 2021; 9:e12579. DOI: https://doi.org/10.7717/peerj.12579
19. Rahman TM, Hodgson HJ. Animal models of acute hepatic failure. Int J Exp Pathol 2000; 81(2):145-157. DOI: https://doi.org/10.1046/j.1365-2613.2000.00144.x
20. Humphries C, Dear JW. Novel biomarkers for drug-induced liver injury. Clin Toxicol (Phila) 2023; 61(8):567-572. DOI: https://doi.org/10.1080/15563650.2023.2259089
21. Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022; 7(1):287. DOI: https://doi.org/10.1038/s41392-022-01119-3
How to Cite
Guda, R. (2024). An Update of Ischemic Hepatitis: A Review. Science Insights, 45(1), 1447–1452. https://doi.org/10.15354/si.24.re1037
Issue
Section
Review
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.